检索结果-南通市图书馆

Chinese Journal of Integrative Medicine 2022年第4期28卷 349-356页

作者： XUAN Lei HU Jing-hai BI Ran LIU Si-qi WANG Chun-xi Department of Urology the First Hospital of Jilin UniversityChangchun130021China

Objective:To explore the influences of andrographolide(Andro)on bladder cancer cell lines and a tumor xenograft mouse model bearing 5637 cells.Methods:For in vitro experiments,T24 cells were stimulated with Andro(0-40μmol/L)and 5637 cells were stimulated with Andro(0 to 80μmol/L).Cell growth,migration,and infiltration were assessed using cel counting kit-8,colony formation,wound healing,and transwel assays.Apoptosis rate was examined using flow cytometry.In in vivo study,the antitumor effect of Andro(10 mg/kg)was evaluated by 5637 tumor-bearing mice,and levels of nuclear factorκB(NF-κB)and phosphoinositide 3-kinase/AKT related-proteins were determined by immunoblotting.Results:Andro suppressed growth,migration,and infiltraion of bladder cancer cells(P 0.05or P 0.01).Additionally,Andro induced intrinsic mitochondria-dependent apoptosis in bladder cancer cell lines.Furthermore,Andro inhibited bladder cancer growth in mice(P 0.01).The expression of p65,p-AKT were suppressed by Andro treatment in vitro and in vivo(P 0.05 or P 0.01).Conclusions:Andrographolide inhibits proliferation and promotes apoptosis in bladder cancer cel s by interfering with NF-κB and PI3K/AKT signaling in vitro and in vivo.

关键词： andrographolide Chinese medicine bladder cancer nuclear factorκB PI3K-AKT

Treatment and surveillance for non-muscle-invasive bladder cancer:a clinical practice guideline(2021 edition)

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Military Medical Research 2023年第2期10卷 141-161页

作者： Ying-Hui Jin Xian-Tao Zeng Tong-Zu Liu Zhi-Ming Bai Zhong-Ling Dou De-Gang Ding Zhi-Lu Fan Ping Han Yi-Ran Huang Xing Huang Ming Li Xiao-Dong Li Yi-Ning Li Xu-Hui Li Chao-Zhao Liang Jiu-Min Liu Hong-Shun Ma Juan Qi Jia-Qi Shi Jian Wang De-Lin Wang Zhi-Ping Wang Yun-Yun Wang Yong-Bo Wang Qiang Wei Hai-Bo Xia Jin-Chun Xing Si-Yu Yan Xue-Pei Zhang Guo-You Zheng Nian-Zeng Xing Da-Lin He Xing-Huan Wang on behalf of the Chinese Urological Doctor Association(CUDA),Urological Association of Chinese Research Hospital Association(CRHA-UA),Uro-Health Promotive Association of China International Exchange,Promotive Association for Medical,Health Care(CPAM-UHPA) Center for Evidence-Based and Translational Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Urology Institute of UrologyZhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Urology Haikou People’s HospitalHaikou Afliated Hospital of Central South University Xiangya School of MedicineHaikou 570208China Department of Urology the First Afliated Hospital and College of Clinical MedicineHenan University of Science and TechnologyLuoyang 450052HenanChina Department of Urology Henan Provincial People’s Hospi-talZhengzhou University People’s HospitalZhengzhou 450003China Department of Urology the Second Hospital of Dalian Medical UniversityDalian 116023LiaoningChina Department of Urology Institute of UrologyWest China HospitalSichuan UniversityChengdu 610041China Department of Urology Renji HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai 200120China Department of Urology the People’s Hos-pital of Xinjiang Uygur Autonomous RegionUrumqi 830002China Depart-ment of Urology Huaihe Hospital of Henan UniversityKaifeng 475000HenanChina Institutes of Evidence-Based Medicine and Knowledge Translation Henan UniversityKaifeng 475000HenanChina Department of Urology the Second Afliated Hospital and Second Clinical Medical College of Fujian Medical UniversityQuanzhou 362000FujianChina Department of Urol-ogy the First Afliated Hospital of Anhui Medical UniversityHefei 230022China Department of Urology Guangdong Provincial People’s HospitalGuangdong Academy of Medical SciencesGuangzhou 510080China Department of Urology Tianjin First Central HospitalTianjin 300190China Department of Urology Xinhua HospitalSchool of MedicineShanghai Jiao Tong University School of MedicineShanghai 200092China Department of Urology Afliated Hospital of Guizhou Medical UniversityGuiyang 550004China Department of Urology Qinghai University Afliated HospitalXining 810012China Department of Urology the First Afliated Hospital of Chongqing Medical Univ

Non-muscle invasive bladder cancer(NMIBC)is a major type of bladder cancer with a high incidence worldwide,resulting in a great disease burden.Treatment and surveillance are the most important part of NIMBC management.In 2018,we issued“Treatment and surveillance for non-muscle-invasive bladder cancer in China:an evidencebased clinical practice guideline”.Since then,various studies on the treatment and surveillance of NMIBC have been published.There is a need to incorporate these materials and also to take into account the relatively limited medical resources in primary medical institutions in China.Developing a version of guideline which takes these two issues into account to promote the management of NMIBC is therefore indicated.We formed a working group of clinical experts and methodologists.Through questionnaire investigation of clinicians including primary medical institutions,24 clinically concerned issues,involving transurethral resection of bladder tumor(TURBT),intravesical chemotherapy and intravesical immunotherapy of NMIBC,and follow-up and surveillance of the NMIBC patients,were determined for this guideline.Researches and recommendations on the management of NMIBC in databases,guideline development professional societies and monographs were referred to,and the European Association of Urology was used to assess the certainty of generated recommendations.Finally,we issued 29 statements,among which 22 were strong recommendations,and 7 were weak recommendations.These recommendations cover the topics of TURBT,postoperative chemotherapy after TURBT,Bacillus Calmette–Guérin(BCG)immunotherapy after TURBT,combination treatment of BCG and chemotherapy after TURBT,treatment of carcinoma in situ,radical cystectomy,treatment of NMIBC recurrence,and follow-up and surveillance.We hope these recommendations can help promote the treatment and surveillance of NMIBC in China,especially for the primary medical institutions.

关键词： Non-muscle invasive bladder cancer bladder cancer Transurethral resection of bladder tumor Treatment Surveillance Guideline

Metabolomic and elemental profiling of blood serum in bladder cancer

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Journal of Pharmaceutical Analysis 2022年第6期12卷 889-900页

作者： Krzysztof Ossolinski Tomasz Ruman Valerie Copie Brian P.Tripet Leonardo B.Nogueira Katiane O.P.C.Nogueira Artur Kołodziej Aneta Płaza-Altamer Anna Ossolinska Tadeusz Ossolinski Joanna Nizioł Department of Urology John Paul II Hospital36-100KolbuszowaPoland Rzeszow University of Technology Faculty of Chemistry35-959RzeszowPoland The Department of Chemistry and Biochemistry Montana State UniversityBozemanMT59717USA Department of Geology Federal University of Ouro Preto35400-000Ouro PretoBrazil Department of Biological Sciences Federal University of Ouro Preto35400-000Ouro PretoBrazil Doctoral School of Engineering and Technical Sciences at the Rzeszow University of Technology 35-959RzeszowPoland

bladder cancer(BC)is one of the most frequently diagnosed types of urinary cancer.Despite advances in treatment methods,no specific biomarkers are currently in use.Targeted and untargeted profiling of metabolites and elements of human blood serum from 100 BC patients and the same number of normal controls(NCs),with external validation,was attempted using three analytical methods,i.e.,nuclear magnetic resonance,gold and silver-109 nanoparticle-based laser desorption/ionization mass spectrometry(LDI-MS),and inductively coupled plasma optical emission spectrometry(ICP-OES).All results were subjected to multivariate statistical analysis.Four potential serum biomarkers of BC,namely,isobutyrate,pyroglutamate,choline,and acetate,were quantified with proton nuclear magnetic resonance,which had excellent predictive ability as judged by the area under the curve(AUC)value of 0.999.Two elements,Li and Fe,were also found to distinguish between cancer and control samples,as judged from ICP-OES data and AUC of 0.807(in validation set).Twenty-five putatively identified compounds,mostly related to glycans and lipids,differentiated BC from NCs,as detected using LDI-MS.Five serum metabolites were found to discriminate between tumor grades and nine metabolites between tumor stages.The results from three different analytical platforms demonstrate that the identified distinct serum metabolites and metal elements have potential to be used for noninvasive detection,staging,and grading of BC.

关键词： bladder cancer Biomarkers Human serum Metallomics Metabolomics

Current and Potential Roles of Ferroptosis in bladder cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Current Medical Science 2024年第1期44卷 51-63页

作者： Wen-xin AN Radheshyam Gupta Kun ZHAI Ya-ru WANG Wan-hai XU Yan CUI Department of Urology Harbin Medical University Cancer HospitalHarbin 150081China Department of Internal Medical Oncology Harbin Medical University Cancer HospitalHarbin 150081China

Ferroptosis,a type of regulated cell death driven by iron-dependent lipid peroxidation,is mainly initiated by extramitochondrial lipid peroxidation due to the accumulation of iron-dependent reactive oxygen species.Ferroptosis is a prevalent and primitive form of cell death.Numerous cellular metabolic processes regulate ferroptosis,including redox homeostasis,iron regulation,mitochondrial activity,amino acid metabolism,lipid metabolism,and various disease-related signaling pathways.Ferroptosis plays a pivotal role in cancer therapy,particularly in the eradication of aggressive malignancies resistant to conventional treatments.Multiple studies have explored the connection between ferroptosis and bladder cancer,focusing on its incidence and treatment outcomes.Several biomolecules and tumor-associated signaling pathways,such as p53,heat shock protein 1,nuclear receptor coactivator 4,RAS-RAF-MEK,phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin,and the Hippo-tafazzin signaling system,exert a moderating influence on ferroptosis in bladder cancer.Ferroptosis inducers,including erastin,artemisinin,conjugated polymer nanoparticles,and quinazolinyl-arylurea derivatives,hold promise for enhancing the effectiveness of conventional anticancer medications in bladder cancer treatment.Combining conventional therapeutic drugs and treatment methods related to ferroptosis offers a promising approach for the treatment of bladder cancer.In this review,we analyze the research on ferroptosis to augment the efficacy of bladder cancer treatment.

关键词： ferroptosis bladder cancer ferroptosis-associated tumor signaling pathway ferroptosis inducer

Application of synthetic biology in bladder cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2022年第18期135卷 2178-2187页

作者： Mengting Ding Jiaxing Lin Caipeng Qin Ping Wei Jiahe Tian Tianxin Lin Tao Xu Department of Urology Peking University People’s HospitalBeijing 100044China Center for Cell and Gene Circuit Design CAS Key Laboratory of Quantitative Engineering BiologyShenzhen Institute of Synthetic BiologyShenzhen Institute of Advanced TechnologyChinese Academy of SciencesShenzhenGuangdong 518055China Department of Biological Sciences University of Southern CaliforniaLos AngelesCA 90089USA Department of Urology Sun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhouGuangdong 528403China

bladder cancer(BC)is the most common malignant tumor of the genitourinary system.The age of individuals diagnosed with BC tends to decrease in recent years.A variety of standard therapeutic options are available for the clinical management of BC,but limitations exist.It is difficult to surgically eliminate small lesions,while radiation and chemotherapy damage normal tissues,leading to severe side effects.Therefore,new approaches are required to improve the efficacy and specificity of BC treatment.Synthetic biology is a field emerging in the last decade that refers to biological elements,devices,and materials that are artificially synthesized according to users’needs.In this review,we discuss how to utilize genetic elements to regulate BC-related gene expression periodically and quantitatively to inhibit the initiation and progression of BC.In addition,the design and construction of gene circuits to distinguish cancer cells from normal cells to kill the former but spare the latter are elaborated.Then,we introduce the development of genetically modified T cells for targeted attacks on BC.Finally,synthetic nanomaterials specializing in detecting and killing BC cells are detailed.This review aims to describe the innovative details of the clinical diagnosis and treatment of BC from the perspective of synthetic biology.

关键词： bladder cancer Synthetic biology Gene circuits T cell immunotherapy Nanomaterials

Antioxidant status in patients with bladder cancer regarding cancer stage and grade

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Asian Journal of Urology 2023年第2期10卷 182-188页

作者： Zahid Lepara Jasmin Alic Orhan Lepara Hajrudin Spahovic Almir Fajkic Urology Clinic Clinical Center University of SarajevoBolnicka 2571000 SarajevoBosnia and Herzegovina Department of Physiology Faculty of MedicineUniversity of SarajevoCekalu sa 9071000 SarajevoBosnia and Herzegovina Department of Pathophysiology Faculty of MedicineUniversity of SarajevoCekalu sa 9071000 SarajevoBosnia and Herzegovina

Objective:The imbalance of antioxidants and pro-oxidants plays a crucial role in the carcinogenesis of bladder cancer(BC).This study aimed to evaluate serum antioxidant status in patients with BC and determine its potential use in the diagnosis and progression potential considerations following histopathological assessment.Methods:A cross-sectional study included 90 patients with BC,divided into Ta,T1,and T2eT4 stage subgroups,and according to cancer progression potential,into low-grade(LG)and highgrade(HG)subgroups.The control group(CG)included 30 healthy volunteers.Antioxidant status was determined using the spectrophotometric method and standard laboratory tests.Results:Serum superoxide dismutase activity was significantly higher in BC patients regarding cancer stage in comparison to the CG(p<0.001).Catalase activity was highest in T2eT4 subgroup and was significantly higher compared to the Ta(p<0.01)and T1(p<0.05)subgroups.Serum albumin level was significantly lower in the BC group compared to the CG(p<0.001).In addition,it was significantly lower in T2eT4 subgroup compared to T1 and Ta subgroups(p<0.01).A significant negative correlation was found between tumor size and serum albumin level only(r=0.386,p<0.01).Catalase activity was higher in HG subgroup(p=0.009),while bilirubin level was higher in LG subgroup(p=0.035).The optimal cut-off value of catalase activity in differentiating patients with LG and HG BC subgroups was 11.96 IU/L,and the specificity and sensitivity were 51.1% and 82.2%,respectively.Bilirubin level,for a calculated optimal cut-off value of 11.95 mmol/L,had a specificity of 44.1%and sensitivity of 80.0%.Conclusion:More invasive stages of BC with greater progression potential are associated with an increase in enzymatic antioxidant activity and a decrease in non-enzymatic antioxidant capacity.It may suggest a possible role of antioxidants in the prediction and monitoring of illness trajectory.

关键词： bladder cancer Antioxidant Superoxide dismutase Catalase Serum albumin

ARID1A Inactivation Increases Expression of circ0008399 and Promotes Cisplatin Resistance in bladder cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

当代医学科学(英文) 2023年第3期43卷 560-571页

作者： Yang-kai JIANG Yu-jun SHUAI Hua-min DING Hui ZHANG Chao HUANG Liang WANG Jia-yin SUN Wen-jie WEI Xing-yuan XIAO Guo-song JIANG Department of Urology Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430022China Department of Urology Jingshan Union Hospital of Huazhong University of Science and Technology(People's Hospital of Jingshan)Jingshan 431899China

Objective Cisplatin(CDDP)-based chemotherapy is a first-line,drug regimen for muscle-invasive bladder cancer(BC)and metastatic bladder cancer.Clinically,resistance to CDDP restricts the clinical benefit of some bladder cancer patients.AT-rich interaction domain 1A(ARID1A)gene mutation occurs frequently in bladder cancer;however,the role of CDDP sensitivity in BC has not been studied.Methods We established ARID1A knockout BC cell lines using CRISPR/Cas9 technology.IC50 determination,flow cytometry analysis of apoptosis,and tumor xenograft assays were performed to verify changes in the CDDP sensitivity of BC cells losing ARID1A.qRT-PCR,Western blotting,RNA interference,bioinformatic analysis,and ChIP-qPCR analysis were performed to further explore the potential mechanism of ARID1A inactivation in CDDP sensitivity in BC.Results It was found that ARID1A inactivation was associated with CDDP resistance in BC cells.Mechanically,loss of ARID1A promoted the expression of eukaryotic translation initiation factor 4A3(EIF4A3)through epigenetic regulation.Increased expression of EIF4A3 promoted the expression of hsa_circ_0008399(circ0008399),a novel circular RNA(circRNA)identified in our previous study,which,to some extent,showed that ARID1A deletion caused CDDP resistance through the inhibitory effect of circ0008399 on the apoptosis of BC cells.Importantly,EIF4A3-IN-2 specifically inhibited the activity of EIF4A3 to reduce circ0008399 production and restored the sensitivity of ARID1A inactivated BC cells to CDDP.Conclusion Our research deepens the understanding of the mechanisms of CDDP resistance in BC and elucidates a potential strategy to improve the efficacy of CDDP in BC patients with ARID1A deletion through combination therapy targeting EIF4A3.

关键词： AT-rich interaction domain 1A hsa_circ_0008399 eukaryotic translation initiation factor 4A3 cisplatin resistance bladder cancer

Smart nanocarriers as therapeutic platforms for bladder cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Nano Research 2022年第3期15卷 2157-2176页

作者： Tongyu Tong Yupeng Guan Yuanji Gao Chengyuan Xing Shiqiang Zhang Donggen Jiang Xiangwei Yang Yang Kang Jun Pang Department of Urology Kidney and Urology Centerthe Seventh Affiliated HospitalSun Yat-sen UniversityShenzhen 518107China Scientific Research Center the Seventh Affiliated HospitalSun Yat-sen UniversityShenzhen 518107China College of Chemistry and Materials Science Sichuan Normal UniversityChengdu 610068China

Although patients benefit from surgical transurethral resection of bladder cancers,some niduses are missed or incompletely resected,and small malignant lesions may recur.Intravesical chemotherapy and immunotherapy are universally accepted as adjuvant treatments after surgery to avoid recurrence and progression.However,these treatments still have limitations,including an insufficient retention period,inefficient permeability of chemotherapeutic agents,and dilution of the agents by urine.Nanostructure-based smart therapeutic platforms can be tailored to be responsive to internal or external stimuli to ameliorate this situation.This unparalleled capability empowers the precise aggregation of stimulus–responsive nanocarriers in the target regions,namely,the tumors,and subsequent release of the anticancer materials.This review summarizes the current nanostructure-based therapeutic platforms,especially stimulus–responsive nanocarriers,and highlights their benefits and limitations in bladder cancer therapy.Novel innovations in nanotechnology have undoubtedly arrived at a new height and have become useful for practical applications.Nanotechnology will positively promote the development of anticancer agents not only for bladder cancer but also for other solid tumors.

关键词： nanocarriers stimulus-responsive therapeutic platform drug delivery bladder cancer

MiR-183-5p-PNPT1 Axis Enhances Cisplatin-induced Apoptosis in bladder cancer Cells

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Current Medical Science 2022年第4期42卷 785-796页

作者： Qing-gang HU Zhi YANG Jia-wei CHEN Gallina KAZOBINKA Liang TIAN Wen-cheng LI Department of Urology Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430022China Department of Hepatobiliary Surgery Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430022China Department of Urology Luoshan County People’s HospitalXinyang 464000China Urology Unit La Nouvelle Polyclinique Centrale de BujumburaBujumbura 378Burundi Department of Urology Wuhan Red Cross HospitalWuhan 430015China

Objective:It has been reported that intrinsic apoptosis is associated with the progression of bladder cancer(BC).Recent evidence suggests that polyribonucleotide nucleotidyltransferase 1(PNPT1)is a pivotal mediator involved in RNA decay and cell apoptosis.However,the regulation and roles of PNPT1 in bladder cancer remain largely unclear.Methods:The upstream miRNA regulators were predicted by in silico analysis.The expression levels of PNPT1 were evaluated by real-time PCR,Western blotting,and immunohistochemistry(IHC),while miR-183-5p levels were evaluated by qPCR in BC cell lines and tissues.In vitro and in vivo assays were performed to investigate the function of miR-183-5p and PNPT1 in apoptotic RNA decay and the tumorigenic capability of bladder cancer cells.Results:PNPT1 expression was decreased in BC tissues and cell lines.Overexpression of PNPT1 significantly promoted cisplatin-induced intrinsic apoptosis of BC cells,whereas depletion of PNPT1 potently alleviated these effects.Moreover,oncogenic miR183-5p directly targeted the 3′UTR of PNPT1 and reversed the tumor suppressive role of PNPT1.Intriguingly,miR-183-5p modulated not only PNPT1 but also Bcl2 modifying factor(BMF)to inhibit the mitochondrial outer membrane permeabilization(MOMP)in BC cells.Conclusion:Our results provide new insight into the mechanisms underlying intrinsic apoptosis in BC,suggesting that the miR-183-5p-PNPT1 regulatory axis regulates the apoptosis of BC cells and might represent a potential therapeutic avenue for the treatment of BC.

关键词： bladder cancer polyribonucleotide nucleotidyltransferase 1 bcl2 modifying factor mitochondrial outer membrane permeabilization microRNA

Metabolomics for the diagnosis of bladder cancer: A systematic review

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Asian Journal of Urology 2024年第2期11卷 221-241页

作者： Herney Andrés García-Perdomo Angélica María Dávila-Raigoza Fernando Korkes Division of Urology/Urooncology Department of SurgerySchool of MedicineUniversidad del ValleCaliColombia UROGIV Research Group School of MedicineUniversidad del ValleCaliColombia Urologic Oncology Division of UrologyABC Medical SchoolSao PauloBrazil

Objective: Metabolomics has been extensively utilized in bladder cancer (BCa) research, employing mass spectrometry and nuclear magnetic resonance spectroscopy to compare various variables (tissues, serum, blood, and urine). This study aimed to identify potential biomarkers for early BCa diagnosis.Methods: A search strategy was designed to identify clinical trials, descriptive and analytical observational studies from databases such as Medline, Embase, Cochrane Central Register of Controlled Trials, and Latin American and Caribbean Literature in Health Sciences. Inclusion criteria comprised studies involving BCa tissue, serum, blood, or urine profiling using widely adopted metabolomics techniques like mass spectrometry and nuclear magnetic resonance. Primary outcomes included description of metabolites and metabolomics profiling in BCa patients and the association of metabolites and metabolomics profiling with BCa diagnosis compared to control patients. The risk of bias was assessed using the Quality Assessment of Studies of Diagnostic Accuracy.Results: The search strategy yielded 2832 studies, of which 30 case-control studies were included. Urine was predominantly used as the primary sample for metabolite identification. Risk of bias was often unclear inpatient selection, blinding of the index test, and reference standard assessment, but no applicability concerns were observed. Metabolites and metabolomics profiles associated with BCa diagnosis were identified in glucose, amino acids, nucleotides, lipids, and aldehydes metabolism.Conclusion: The identified metabolites in urine included citric acid, valine, tryptophan, taurine, aspartic acid, uridine, ribose, phosphocholine, and carnitine. Tissue samples exhibited elevated levels of lactic acid, amino acids, and lipids. Consistent findings across tissue, urine, and serum samples revealed downregulation of citric acid and upregulation of lactic acid, valine, tryptophan, taurine, glutamine, aspartic acid, uridine, ribose, and phosphocholine.

关键词： Metabolite Metabolomics bladder cancer Metabolomicsprofile